Elucidating the molecular pathogenesis of NSCLC has led to the discovery of a number of driver mutations, especially in various receptor tyrosine kinases (3) which are now among the most popular targets for metastatic NSCLC treatment. The gene discussed is NTRK1; the disease is non-small cell lung carcinoma.